

Date: Friday, 26th January 2024
Our Ref: MB/CM FOI 6142

Sid Watkins Building
Lower Lane
Fazakerley
Liverpool L9 7BB
Tel: 01515253611
Fax: 01515295500
Direct Line: 01515563038

Re: Freedom of Information Request FOI 6142

We are writing in response to your request submitted under the Freedom of Information Act, received in this office on 26th January 2024.

Your request was as follows:

I am writing this email to inquire about access to information on generalized Myasthenia Gravis. I would like to submit an FOI request to the NHS Foundation Trust for the following information below:

Time Frame: October 2022 - September 2023

1. How many total generalized Myasthenia Gravis patients were treated in the hospitals (Inpatient & Outpatient)

I can confirm between October 2022 and September 2023, the Walton Centre NHS Foundation Trust treated 443 patients with generalised Myasthenia Gravis.

2. How much volume in mg was used for the following therapies:

Immunosuppressants

- a. Azathioprine
- b. Methotrexate
- c. Mycophenolate mofetil

Anti-CD20 - Rituximab

- a. MabThera
- b. Rituximab Biosimilars

Anti-FcRn

- a. Vyvgart (Efgartigimod)

Complement Inhibitors

- a. Soliris (Eculizumab)
- b. Ultomiris (Ravulizumab)

Immunosuppressants - these are prescribed by GPs under a shared care agreement and WCFT do not hold this information.



Anti-CD20 - Rituximab - WCFT use Rituximab for a variety of different Neurological conditions at a standard dosing of Rituximab 1g STAT regimes repeated not sooner than 6 months based on clinical decision. Pharmacy are not informed if this will be for MG, so we are unable to provide information on the total mg used.

Anti-FcRn - a. Vyvgart (Efgartigimod) - approx. 124400mg in total on weight based cycles during the period requested.

Complement Inhibitors - I can confirm these are not used for Myasthenia at WCFT.

Please see our response above in blue.

Re-Use of Public Sector Information

All information supplied by the Trust in answering a request for information (RFI) under the Freedom of Information Act 2000 will be subject to the terms of the Re-use of Public Sector Information Regulations 2005, Statutory Instrument 2005 No. 1515 which came into effect on 1st July 2005.

Under the terms of the Regulations, the Trust will licence the re-use of any or all information supplied if being used in a form and for the purpose other than which it was originally supplied. This license for re-use will be in line with the requirements of the Regulations and the licensing terms and fees as laid down by the Office of Public Sector Information (OPSI). Most licenses will be free; however the Trust reserves the right, in certain circumstances, to charge a fee for the re-use of some information which it deems to be of commercial value.

Further information can be found at www.opsi.gov.uk where a sample license terms and fees can be found with guidance on copyright and publishing notes and a Guide to Best Practice and regulated advice and case studies, at www.opsi.gov.uk/advice/psi-regulations/index.htm

If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to the Freedom of Information Office at the address above.

Please remember to quote the reference number, FOI 6142 in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted by:

Post: Information Commissioners Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

Online: <https://ico.org.uk/make-a-complaint/foi-and-eir-complaints/>

Telephone: 0303 123 1113

Yours sincerely

Mike Burns

Mr. Mike Burns, Executive Lead for Freedom of Information